September 2024
Eli Lilly Partners with Genetic Leap in $409 Million AI-Driven Drug Development Deal
Eli Lilly, Genetic Leap, AI-powered drug deal, oligonucleotide therapy, pharmaceutical partnership
FDA Raises Concerns Over Inappropriate Use of Iterum’s Antibiotic Ahead of Advisory Committee Meeting
Iterum Therapeutics, FDA, antibiotic resistance, sulopenem etzadroxil/probenecid, uncomplicated urinary tract infections (uUTIs), advisory committee meeting
Abbott Launches Lingo, First Over-the-Counter Continuous Glucose Monitor for Health and Wellness in the US
Abbott, Lingo, Over-the-Counter CGM, Health and Wellness, Continuous Glucose Monitoring
Johnson & Johnson Boosts Talc Settlement by $1.1 Billion Amid Ongoing Negotiations
Johnson & Johnson, Talc Settlement, $1.1 Billion Increase, Cancer Lawsuits, Bankruptcy Plan
European Court Suspends EC’s Decision to Revoke Ocaliva’s Marketing Authorization
Ocaliva, European Court, EC decision, marketing authorization, primary biliary cholangitis, PBC, Advanz Pharma
Eli Lilly’s Weekly Insulin Efsitora Alfa Shows Promising Results in Late-Stage Trials
Eli Lilly, weekly insulin, efsitora alfa, type 2 diabetes, Phase III trials, QWINT-1, QWINT-3, insulin therapy, diabetes management
BioMarin Undergoes Strategic Restructuring Amid Slow Roctavian Sales and Staff Layoffs
BioMarin, restructuring, Roctavian, staff layoffs, corporate strategy, hemophilia gene therapy
Astellas Closes California Facility; Takeda Expands ADHD Drug Production Amid Generic Competition
Astellas, Takeda, ADHD drug, Vyvanse, generic competition, facility closure
Novartis Expands Radioligand Therapy Manufacturing with $200M Investment in Two US Sites
Novartis, radioligand therapy, manufacturing expansion, $200M investment, California, Indianapolis
IN8bio Shifts Focus to Leukemia Cell Therapy, Halts Glioblastoma Trial and Reduces Workforce
IN8bio, glioblastoma trial halt, workforce reduction, leukemia cell therapy, gamma-delta T cell therapies